新冠疫情暴发后大量COVID-19干预性临床试验迅速注册:一项描述性分析
该研究于2020年5月15日检索WHO国际临床试验注册平台,纳入1,308项COVID-19相关干预性试验,描述其设计、状态、分期、主要终点、干预措施和地域分布等特征。多数试验注册于ClinicalTrials.gov(703项,53.7%)和中国临床试验注册中心,药物干预最常见,但仅8项试验有同行评议结果发表。
要点
- 疫情初期COVID-19干预性试验注册数量大,药物干预为主。
- 超半数试验已招募受试者,但发表同行评议结果的仅8项。
- 试验完成、发表并转化至实践是真正挑战。
核心结论
- COVID-19相关干预性临床试验注册数量较多,但已发表结果极少。
- 研究界初期响应及时,但试验完成、发表和转化面临挑战。
研究设计与样本
- 描述性分析,检索WHO国际临床试验注册平台2020年5月15日数据。
- 纳入1,308项COVID-19相关注册干预性试验。
- 提取并分析研究设计、状态、分期、主要终点、干预措施和地域等特征。
主要发现
- 多数试验注册于ClinicalTrials.gov(703项,53.7%)和中国临床试验注册中心(291项,22.2%)。
- 试验计划招募总人数734,657,中位每项试验110人。
- 药物干预最常见(763项,58.3%),其中抗寄生虫药物为最常见亚类。
- 超半数试验处于招募状态,但仅8项有同行评议结果发表。
临床怎么用
- 提示临床研究者关注试验完成与结果发表,避免重复注册。
- 药物干预试验集中,需注意抗寄生虫药物等亚类的证据产出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: There is a pressing need for evidence-based interventions to address the devastating clinical and public health effects of the coronavirus disease 2019 (COVID-19) pandemic. The number of registered trials related to COVID-19 is increasing by the day. The objective of this study was to describe the characteristics of the currently registered interventional clinical trials related to COVID-19. METHODS: We searched the World Health Organization's International Clinical Trials Registry Platform on May 15th, 2020. We included any entry that is related to COVID-19. We abstracted and then descriptively analyzed the following characteristics of the registered trials: study design, status, phase, primary endpoints, experimental interventions, and geographic location among other qualifiers. RESULTS: We identified 1,308 eligible registered trials. Most trials were registered with ClinicalTrials.gov (n = 703; 53.7%) and the Chinese Clinical Trial Registry (n = 291; 22.2%). The number of participants to be enrolled across these trials was 734,657, with a median of 110 participants per trial. The most commonly studied intervention category was pharmacologic (n = 763; 58.3%), with antiparasitic medications being the most common subcategory. Although over half of the trials were already recruiting, we identified published peer-reviewed results for only 8 of those trials. CONCLUSION: There is a relatively large number of registered trials but with very few results published so far. Although our findings suggest an appropriate initial response by the research community, the real challenge will be to get these trials completed, published, and translated into practice and policy.
引用
- Nasrallah AA, Farran SH, Nasrallah ZA, et al. A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis. J Clin Epidemiol. 2020. PMID: 32526460. doi:10.1016/j.jclinepi.2020.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。